See what you could detect before you commit a sample.

Peer-reviewed papers, each with a plain-language note on what the result means for you and a permanent link to the source.

Deep reviews by indication: paediatric solid tumours, and CNS tumours read in cerebrospinal fluid. The evidence, the data, and what each lets you do.

Practical guides from our scientific team, starting with how to design a ctDNA endpoint into an oncology trial.

What CSF ctDNA lets neuro-oncology teams do that plasma cannot, with the sensitivity data and the Epistamai Bio case behind it.

What ultra-sensitive ctDNA lets paediatric teams do that they currently cannot, with the sensitivity data and evidence behind it.

For pharma and CRO teams: MRD enrichment, response monitoring and ctDNA endpoints, and how they cut trial size and cost.